20 ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI-PEG 20 ANTIBODIES FOR CANCER TREATMENT

• Main Authors: CHEN LI CHANG, SHOWALTER RICHARD E, ALMASSY ROBERT, LEE YANG, THOMSON JAMES A, SISSON WES, SHIA WEI JONG
• Format: Patent
• Language: English; Korean
• Published: 10.06.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

본 발명은 일반적으로 ADI-PEG 20에 비해 항-ADI-PEG 20 항체와의 감소된 교차-반응성을 갖지만, ADI-PEG 20과 비슷하거나 또는 더 양호한 기능적 특징을 가질 수 있는 단리된 아르기닌 탈이민효소(ADI) 단백질, ADI 단백질을 포함하는 조성물 및 암과 같은 아르기닌-의존성 질환 또는 관련 질환을 치료하는 관련된 방법에 관한 것이다. The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.